ABL1 and Patent ductus arteriosus: The identified target audience for the PDA included adult patients with chronic-phase CML treated with TKIs (imatinib, dasatinib, bosutinib, nilotinib, ponatinib) with a sustained major molecular response (MMR) (BCR-ABL1 levels ≤ 0.1%) for ≥ 6 months.